These results not only illustrate the therapeutic potential of inhibiting TLR-4/MyD88/NF-κB pathways in treating ALI/ARDS via intratracheal delivery of nano-formulated SsnB, but also affirm the role of SsnB as a TLR-4 inhibitor. This evidence concerns the gene MYD88 and acute respiratory distress syndrome.